UBE3A

Ubiquitin-protein ligase E3A · Q05086 · UBE3A on Sugi Atlas →

0 patent compounds predicted against UBE3A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to UBE3A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Trial of Levodopa in Angelman Syndrome PHASE2/PHASE3COMPLETED
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) PHASE3ACTIVE_NOT_RECRUITING
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine PHASE3UNKNOWN
BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. PHASE3NOT_YET_RECRUITING
Study to Compare the Safety and Efficacy of UB-851 and Eprex® PHASE3COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Olaparib in Patients With HRD Malignant Mesothelioma PHASE2RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) PHASE2RECRUITING
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer PHASE2UNKNOWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome PHASE2RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) PHASE1COMPLETED
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome PHASE1RECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
A Natural History Study of Angelman Syndrome nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Minocycline in the Treatment of Angelman Syndrome nanCOMPLETED
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome nanRECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Characterization of Angelman Syndrome nanCOMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Endocrine Disruptors and Life STILe in Breast Cancer Development nanUNKNOWN
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
18F-FDG PET/TC in TIR3A e TIR3B nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a UBE3A binder may also engage these)

ProteinNameSimilarity
O08759 1.000 O08759 →
Q8CDU6 0.980 Q8CDU6 →
Q5RD78 0.980 Q5RD78 →
Q5U5R9 0.979 Q5U5R9 →
Q8IYU2 0.978 Q8IYU2 →
Q3U0D9 0.977 Q3U0D9 →
E1C656 0.975 E1C656 →
PI4KB Phosphatidylinositol 4-kinase beta 0.975 landscape →
A4IID4 0.975 A4IID4 →
B1MTG7 0.974 B1MTG7 →
F8W2M1 0.974 F8W2M1 →
Q6GN16 0.974 Q6GN16 →
O08561 0.974 O08561 →
B0KWC1 0.974 B0KWC1 →
Q8CHG5 0.973 Q8CHG5 →
Q28BK1 0.973 Q28BK1 →
O02810 0.972 O02810 →
A2APV2 0.972 A2APV2 →
B2KI64 0.972 B2KI64 →
Q5PQN1 0.971 Q5PQN1 →
ARFGEF1 Brefeldin A-inhibited guanine nucleotide-exchange protein 1 0.971 landscape →
Q60HG1 0.971 Q60HG1 →
Q6P2K6 0.971 Q6P2K6 →
B4UT09 0.971 B4UT09 →
Q5GLZ8 0.971 Q5GLZ8 →
O15033 0.970 O15033 →
Q9Y6D5 0.970 Q9Y6D5 →
Q1RMT1 0.970 Q1RMT1 →
Q8BKC8 0.970 Q8BKC8 →
Q4G005 0.970 Q4G005 →